Statistics

Total Visits

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r62

Select a period of time:

Number of views in the range

Views
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r24

Views

Views
June 20250
July 202514
August 20252
September 20251
October 20251
November 20256
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States12
Brazil8
United Kingdom1
Italy1
Trinidad and Tobago1
South Africa1
 

Top cities views

Views
Ashburn2
Bastrop1
Bedford1
Belford Roxo1
Caratinga1
Centurion1
Chaguanas1
Dallas1
Elgin1
Fort Worth1